Blau Farmaceutica (BSP:BLAU3) ROCE % : 44.38% (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Blau Farmaceutica ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Blau Farmaceutica's annualized ROCE % for the quarter that ended in Dec. 2023 was 44.38%.

Blau Farmaceutica ROCE % Historical Data

The historical data trend for Blau Farmaceutica's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Blau Farmaceutica ROCE % Chart

Blau Farmaceutica Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

67.26

53.29

35.20

24.36

15.12

Blau Farmaceutica Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
ROCE %	Get a 7-Day Free Trial															24.34	11.90	18.16	-13.32	44.38

Blau Farmaceutica ROCE % Calculation

Blau Farmaceutica's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	366.343	/	( ( (2499.048 - 371.113)	+	(3053.528 - 335.926) )	/ 2 )
	=	366.343	/	( (2127.935	+	2717.602)	/ 2 )
	=	366.343	/	2422.7685
	=	15.12 %

Blau Farmaceutica's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	1180.34	/	( ( (3074.044 - 472.397)	+	(3053.528 - 335.926) )	/ 2 )
	=	1180.34	/	( ( 2601.647	+	2717.602 )	/ 2 )
	=	1180.34	/	2659.6245
	=	44.38 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

Blau Farmaceutica (BSP:BLAU3) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Blau Farmaceutica ROCE % Related Terms

Thank you for viewing the detailed overview of Blau Farmaceutica's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Blau Farmaceutica (BSP:BLAU3) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Blau Farmaceutica SA (BSP:BLAU3) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

Rodovia Raposo Tavares, No. 2833, Km 30.5, Barro Branco, Cotia, SP, BRA, 06705-030

Website

https://www.blau.com

Blau Farmaceutica SA is engaged in the manufacturing, development and commercialization of complex private-label drugs for the institutional segment. The Company's business activities cover institutional and retail segments, and are divided into four units: 1) Biologicals are a heterogeneous class of products that can be produced using raw materials from biological materials and biotechnological procedures. 2) Oncology line is made up of oral and injectable drugs intended for treating cancer, which encompasses a number of therapeutic classes. 3) Specialties line is made up of products that are used in the hospital's daily routine, in the specialized treatments for infectious diseases and special treatments. 4) Others consist of prescription and non-prescription over-the-counter drugs.

Blau Farmaceutica (BSP:BLAU3) Headlines

No Headlines